• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

    8.530 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 8.530
    Bid (Size) 7.100 (800)
    Ask (Size) 9.910 (100)
    Prev. Close 8.530
    Today's Range 8.530 - 8.530
    52wk Range 6.420 - 22.90
    Shares Outstanding 16,008,469
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
    Via ACCESS Newswire
    News headline image
    Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
    Via ACCESS Newswire

    Performance

    YTD
    +16.4%
    +16.4%
    1 Month
    -30.6%
    -30.6%
    3 Month
    -39.0%
    -39.0%
    6 Month
    -31.8%
    -31.8%
    1 Year
    -46.7%
    -46.7%

    More News

    Read More
    News headline image
    Cadrenal's Quiet Expansion Play Is Starting to Get Loud
    Via ACCESS Newswire
    News headline image
    Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
    Via ACCESS Newswire
    Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
    Via Get News
    Topics Death Economy
    News headline image
    Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
    From Cadrenal Therapeutics
    Via Business Wire
    News headline image
    Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
    From Cadrenal Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Cadrenal Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cadrenal Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cadrenal Therapeutics, Inc. - Common Stock trade on?
    Cadrenal Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cadrenal Therapeutics, Inc. - Common Stock is CVKD on the Nasdaq Stock Market
    What is the current price of Cadrenal Therapeutics, Inc. - Common Stock?
    The current price of Cadrenal Therapeutics, Inc. - Common Stock is 8.530
    When was Cadrenal Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cadrenal Therapeutics, Inc. - Common Stock was at 01/12/26 04:00 PM ET
    What is the market capitalization of Cadrenal Therapeutics, Inc. - Common Stock?
    The market capitalization of Cadrenal Therapeutics, Inc. - Common Stock is 136.55M
    How many shares of Cadrenal Therapeutics, Inc. - Common Stock are outstanding?
    Cadrenal Therapeutics, Inc. - Common Stock has 137M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.